BioVaxys Technology Corp. (BVAXF)
USD 0.05
(7.06%)
USD 0.05
(7.06%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 113.47 Thousand CAD | -86.89% |
| 2022 | 865.56 Thousand CAD | -89.82% |
| 2021 | 8.5 Million CAD | -18.7% |
| 2020 | 10.45 Million CAD | 3315.01% |
| 2019 | 306.26 Thousand CAD | 181.64% |
| 2018 | 108.74 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.76 Million CAD | 19.66% |
| 2024 Q1 | 1.47 Million CAD | 1200.76% |
| 2024 Q3 | 2.4 Million CAD | 36.31% |
| 2023 Q1 | 1.25 Million CAD | 45.47% |
| 2023 FY | 113.47 Thousand CAD | -86.89% |
| 2023 Q3 | 1.41 Million CAD | -46.75% |
| 2023 Q4 | 113.47 Thousand CAD | -91.97% |
| 2023 Q2 | 2.65 Million CAD | 110.69% |
| 2022 Q1 | 8.03 Million CAD | -5.48% |
| 2022 Q2 | 8 Million CAD | -0.39% |
| 2022 Q4 | 865.56 Thousand CAD | -89.02% |
| 2022 FY | 865.56 Thousand CAD | -89.82% |
| 2022 Q3 | 7.88 Million CAD | -1.49% |
| 2021 Q4 | 8.5 Million CAD | -12.02% |
| 2021 Q3 | 9.66 Million CAD | 8.02% |
| 2021 Q2 | 8.94 Million CAD | 3.11% |
| 2021 Q1 | 8.67 Million CAD | -17.03% |
| 2021 FY | 8.5 Million CAD | -18.7% |
| 2020 Q1 | 286.35 Thousand CAD | -6.5% |
| 2020 FY | 10.45 Million CAD | 3315.01% |
| 2020 Q4 | 10.45 Million CAD | 1196.41% |
| 2020 Q3 | 806.76 Thousand CAD | 205.69% |
| 2020 Q2 | 263.91 Thousand CAD | -7.84% |
| 2019 FY | 306.26 Thousand CAD | 181.64% |
| 2019 Q4 | 306.26 Thousand CAD | -12.4% |
| 2019 Q2 | 391.27 Thousand CAD | -6.47% |
| 2019 Q1 | 418.36 Thousand CAD | 0.0% |
| 2019 Q3 | 349.59 Thousand CAD | -10.65% |
| 2018 FY | 108.74 Thousand CAD | 0.0% |
| 2018 Q3 | 89.47 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.708% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 98.428% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.894% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 98.925% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.913% |
| Mesoblast Limited | 667.9 Million USD | 99.983% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -56.813% |
| Genus plc | 1.02 Billion USD | 99.989% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 91.646% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 77.261% |
| Marizyme, Inc. | 22.01 Million USD | 99.485% |
| ContraFect Corporation | 20.67 Million USD | 99.451% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 81.901% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 70.93% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 70.307% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 92.076% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 97.263% |
| MultiCell Technologies, Inc. | 126.22 USD | -89804.928% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 87.924% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.912% |
| EV Biologics, Inc. | 431.71 Thousand USD | 73.715% |
| Q BioMed Inc. | 3.51 Million USD | 96.772% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.677% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 85.275% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 56.568% |
| Biomind Labs Inc. | 73.81 Thousand USD | -53.725% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 99.975% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.622% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.05% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 96.575% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 95.868% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 94.205% |
| IMV Inc. | 31.33 Million USD | 99.638% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 83.494% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 95.641% |
| GB Sciences, Inc. | 103.44 Thousand USD | -9.702% |
| Alpha Cognition Inc. | 2.45 Million USD | 95.372% |
| HST Global, Inc. | 1526.00 USD | -7336.304% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Halberd Corporation | 10.13 Thousand USD | -1020.107% |
| Enzolytics Inc. | 361.7 Million USD | 99.969% |
| Resverlogix Corp. | 8.11 Million USD | 98.602% |
| Affymax, Inc. | 7.44 Million USD | 98.475% |
| SYBLEU INC | 330.46 Thousand USD | 65.661% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 93.957% |
| argenx SE | 4.54 Billion USD | 99.998% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.594% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.762% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -398.126% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 98.732% |
| AVAX Technologies, Inc. | 7.37 Million USD | 98.462% |
| Zenith Capital Corp. | 7410.00 USD | -1431.417% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.997% |
| Ember Therapeutics, Inc. | 184.00 USD | -61572.826% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 64.737% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 56.582% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.975% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 92.168% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | 96.249% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.785% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 87.771% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.221% |
| ONE Bio Corp. | 70.08 Million USD | 99.838% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -98.756% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -4812.468% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 88.514% |
| Agentix Corp. | 261.39 Thousand USD | 56.587% |
| LadRx Corporation | 2.3 Million USD | 95.083% |
| Cell Source, Inc. | 195.17 Thousand USD | 41.857% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 76.386% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 67.909% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 67.909% |
| NovAccess Global Inc. | 62.24 Thousand USD | -82.3% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 82.26% |
| Itoco Inc. | 1.4 Million USD | 91.895% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -18.63% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -7.055% |
| Kadimastem Ltd | 2.3 Million USD | 95.075% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -48.621% |
| CytoDyn Inc. | 11.13 Million USD | 98.981% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 20.629% |
| Mobile Lads Corp. | 52.00 USD | -218126.923% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -534.664% |
| Qrons Inc. | 420.00 USD | -26918.571% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 70.561% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 79.447% |
| Rebus Holdings, Inc. | 5000.00 USD | -2169.56% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 72.283% |
| International Stem Cell Corporation | 5.39 Million USD | 97.895% |
| Bioxytran, Inc. | 137.63 Thousand USD | 17.553% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.244% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.316% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -43.643% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 86.876% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 98.49% |
| Neutra Corp. | 2851.00 USD | -3880.288% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.65% |
| PureTech Health plc | 693.97 Million USD | 99.984% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 98.594% |
| IXICO plc | 15.84 Million USD | 99.284% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 98.63% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.89% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.966% |